Liquid biopsy for children with central nervous system tumours: Clinical integration and technical considerations.
CNS tumours
cancer heterogeneity
cell free DNA (cfDNA)
circulating tumour DNA (ctDNA)
liquid bioposy
molecular diagnostics
paediatric oncology
personalised medicine
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
05
2022
accepted:
28
10
2022
entrez:
5
12
2022
pubmed:
6
12
2022
medline:
6
12
2022
Statut:
epublish
Résumé
Circulating cell-free DNA (cfDNA) analysis has the potential to revolutionise the care of patients with cancer and is already moving towards standard of care in some adult malignancies. Evidence for the utility of cfDNA analysis in paediatric cancer patients is also accumulating. In this review we discuss the limitations of blood-based assays in patients with brain tumours and describe the evidence supporting cerebrospinal fluid (CSF) cfDNA analysis. We make recommendations for CSF cfDNA processing to aid the standardisation and technical validation of future assays. We discuss the considerations for interpretation of cfDNA analysis and highlight promising future directions. Overall, cfDNA profiling shows great potential as an adjunct to the analysis of biopsy tissue in paediatric cancer patients, with the potential to provide a genetic molecular profile of the tumour when tissue biopsy is not feasible. However, to fully realise the potential of cfDNA analysis for children with brain tumours larger prospective studies incorporating serial CSF sampling are required.
Identifiants
pubmed: 36467471
doi: 10.3389/fped.2022.957944
pmc: PMC9709284
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
957944Informations de copyright
© 2022 Stankunaite, Marshall, Carceller, Chesler, Hubank and George.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pediatr Blood Cancer. 2019 May;66(5):e27595
pubmed: 30614191
Eur J Cancer. 2022 Jan;160:12-23
pubmed: 34794856
Front Immunol. 2021 Jun 15;12:673248
pubmed: 34211467
Cancers (Basel). 2022 Jan 13;14(2):
pubmed: 35053536
Cell Stem Cell. 2018 Nov 1;23(5):700-713.e6
pubmed: 30388424
J Hepatol. 2017 Aug;67(2):293-301
pubmed: 28323123
J Clin Oncol. 2014 Sep 1;32(25):2727-34
pubmed: 25071110
BMC Med Genomics. 2019 Aug 2;12(1):115
pubmed: 31375105
Science. 2020 Mar 27;367(6485):1449-1454
pubmed: 32217721
Clin Cancer Res. 2016 Nov 15;22(22):5564-5573
pubmed: 27440268
Int J Cancer. 2019 Oct 1;145(7):1889-1901
pubmed: 30861105
Front Cell Dev Biol. 2020 Feb 18;8:45
pubmed: 32133357
Front Neurol. 2020 Oct 19;11:544680
pubmed: 33192972
Nat Commun. 2021 May 28;12(1):3230
pubmed: 34050156
Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4
pubmed: 28803919
Curr Treat Options Oncol. 2019 Nov 29;20(12):88
pubmed: 31784837
Nat Commun. 2015 Nov 10;6:8839
pubmed: 26554728
Neurooncol Adv. 2021 Jan 27;3(1):vdab013
pubmed: 34169282
Mol Cancer. 2021 Feb 12;20(1):32
pubmed: 33579306
Acta Neuropathol Commun. 2020 Nov 5;8(1):182
pubmed: 33153497
Ann Oncol. 2019 Jun 1;30(6):990-997
pubmed: 30916311
CNS Oncol. 2019 Jun;8(2):CNS34
pubmed: 30855176
Eur J Cancer. 2022 Feb;162:209-220
pubmed: 34933802
Sci Rep. 2021 Mar 3;11(1):5098
pubmed: 33658570
J Neurooncol. 2008 Feb;86(3):313-9
pubmed: 17909941
Blood. 2021 May 27;137(21):2992-2997
pubmed: 33598691
Acta Neuropathol Commun. 2018 Aug 15;6(1):80
pubmed: 30111355
Ann Oncol. 2019 Mar 1;30(3):358-359
pubmed: 30649226
J Mol Diagn. 2021 Jun;23(6):742-752
pubmed: 33781965
Nat Commun. 2021 May 27;12(1):3199
pubmed: 34045463
Cancer Cell. 2021 Nov 8;39(11):1519-1530.e4
pubmed: 34678152
Clin Cancer Res. 2018 Nov 1;24(21):5282-5291
pubmed: 29941484
Nat Genet. 2020 Nov;52(11):1219-1226
pubmed: 33106634
Lancet Oncol. 2020 Jun;21(6):e305-e316
pubmed: 32502457
Neuro Oncol. 2022 Aug 1;24(8):1352-1363
pubmed: 34984433
Clin Cancer Res. 2018 Feb 15;24(4):939-949
pubmed: 29191970
Epigenetics. 2021 Jan-Feb;16(2):196-208
pubmed: 32662719
Int J Mol Sci. 2021 Apr 27;22(9):
pubmed: 33925295
Neurosurg Focus. 2020 Jan 1;48(1):E8
pubmed: 31896088
Onco Targets Ther. 2020 Jan 23;13:719-731
pubmed: 32158224
Clin Chem. 2015 Mar;61(3):514-22
pubmed: 25605683
Sci Rep. 2020 Feb 7;10(1):2120
pubmed: 32034265
Nat Med. 2019 Sep;25(9):1415-1421
pubmed: 31501609
Nature. 2016 Jan 21;529(7586):351-7
pubmed: 26760213
Clin Cancer Res. 2020 Dec 1;26(23):6266-6276
pubmed: 33087334
Pediatr Blood Cancer. 2017 Jun;64(6):
pubmed: 27896933
Clin Cancer Res. 2018 Dec 1;24(23):5850-5859
pubmed: 30322880
Acta Neuropathol Commun. 2022 Feb 24;10(1):25
pubmed: 35209946
Cancer Discov. 2022 May 2;12(5):1266-1281
pubmed: 35292802
Acta Neuropathol. 2019 Feb;137(2):297-306
pubmed: 30460397
Cell. 2018 Feb 22;172(5):1050-1062.e14
pubmed: 29474906
Br J Cancer. 2022 Feb;126(3):379-390
pubmed: 34815523
JCO Precis Oncol. 2022 Mar;6:e2100335
pubmed: 35263170
Lab Invest. 2022 Feb;102(2):134-142
pubmed: 34934181
Nat Commun. 2020 Mar 27;11(1):1446
pubmed: 32221288
Mol Cell Probes. 2019 Aug;46:101411
pubmed: 31173881
Neurosurg Focus. 2020 Jan 1;48(1):E9
pubmed: 31896079
Genome Med. 2021 May 31;13(1):96
pubmed: 34059130
Nat Commun. 2021 Apr 21;12(1):2357
pubmed: 33883548
Curr Opin Oncol. 2020 Jan;32(1):68-77
pubmed: 31714259
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Mol Aspects Med. 2020 Apr;72:100819
pubmed: 31563277
Nat Commun. 2012 May 01;3:811
pubmed: 22549840
J Pers Med. 2020 Nov 27;10(4):
pubmed: 33260839
PLoS Genet. 2016 Dec 20;12(12):e1006501
pubmed: 27997549
Nat Commun. 2015 Nov 04;6:8760
pubmed: 26530965
Nature. 2017 Apr 26;545(7655):446-451
pubmed: 28445469
Nat Commun. 2020 Oct 27;11(1):5376
pubmed: 33110059
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Cancers (Basel). 2021 Oct 15;13(20):
pubmed: 34680323
Acta Neuropathol Commun. 2018 Aug 31;6(1):85
pubmed: 30170631
Neuro Oncol. 2021 Sep 1;23(9):1494-1508
pubmed: 33560371
CNS Oncol. 2019 Mar 1;8(1):CNS28
pubmed: 30806082
Br J Haematol. 2018 May;181(4):537-539
pubmed: 28369776
Eur J Pediatr. 2020 Feb;179(2):191-202
pubmed: 31897843
Acta Neuropathol Commun. 2017 Apr 17;5(1):28
pubmed: 28416018
Acta Neuropathol. 2019 Jan;137(1):139-150
pubmed: 30196423
Lancet Oncol. 2020 Jun;21(6):e317-e329
pubmed: 32502458
Sci Adv. 2020 Oct 16;6(42):
pubmed: 33067228
J Clin Oncol. 2016 Jul 10;34(20):2404-15
pubmed: 27161972
Cancers (Basel). 2021 Jun 15;13(12):
pubmed: 34203921
Nature. 2020 Oct;586(7831):763-768
pubmed: 33057201
Oncologist. 2021 Oct;26(10):865-878
pubmed: 34105205
Int J Cancer. 2020 Jun 15;146(12):3369-3378
pubmed: 32159858
Sci Rep. 2021 Mar 11;11(1):5638
pubmed: 33707557
Front Oncol. 2020 Dec 14;10:596191
pubmed: 33381456
Clin Cancer Res. 2021 Jan 1;27(1):169-178
pubmed: 33051308